TWST
Twist Bioscience Corporation NASDAQ Listed Oct 31, 2018$166.99
+7.35%
vs $155.56
Mkt Cap $10.0B
52w Low $25.45
100.0% of range
52w High $166.99
50d MA $118.31
200d MA $69.68
P/E (TTM)
-75.2x
EV/EBITDA
—
P/B
21.1x
Debt/Equity
0.3x
ROE
-16.8%
P/FCF
-132.1x
RSI (14)
70.00
ATR (14)
$9.21
Beta
2.21
50d MA
$118.31
200d MA
$69.68
Avg Volume
1.7M
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
681 Gateway Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | BMO | -0.49 | -0.56 | -14.3% | 91.55 | -10.9% | +10.4% | -1.6% | +15.6% | -5.2% | +6.0% | — |
| May 4, 2026 | BMO | -0.49 | -0.71 | -44.9% | 60.40 | -2.0% | -7.0% | +0.9% | +5.0% | -1.7% | -2.9% | — |
| Feb 2, 2026 | BMO | -0.48 | -0.50 | -4.2% | 46.81 | -0.4% | -1.0% | +3.9% | -2.1% | +4.5% | -3.6% | — |
| Nov 14, 2025 | BMO | -0.50 | -0.45 | +10.0% | 26.87 | -0.5% | -1.5% | -1.7% | -2.1% | +2.4% | +9.6% | — |
| Aug 4, 2025 | BMO | -0.54 | -0.47 | +13.0% | 30.21 | +2.6% | -8.9% | -5.9% | -3.5% | +2.6% | +7.8% | — |
| May 5, 2025 | BMO | -0.56 | -0.66 | -17.9% | 35.93 | -1.7% | -8.9% | +0.1% | -0.5% | -5.5% | +6.9% | — |
| Feb 3, 2025 | BMO | -0.62 | -0.53 | +14.5% | 52.75 | +1.2% | -1.4% | +3.2% | +0.1% | -2.6% | -7.0% | — |
| Nov 18, 2024 | BMO | -0.71 | -0.59 | +17.4% | 41.43 | +0.7% | -0.3% | -0.5% | +1.3% | +1.4% | +9.9% | — |
| Aug 2, 2024 | BMO | -0.79 | -0.86 | -8.9% | 42.97 | -9.3% | +5.5% | +2.0% | -3.7% | +2.0% | -3.2% | — |
| May 2, 2024 | BMO | -0.84 | -0.79 | +6.0% | 32.01 | +19.6% | +28.7% | +8.4% | -3.4% | -4.0% | +4.3% | — |
| Feb 2, 2024 | BMO | -0.80 | -0.75 | +6.2% | 36.59 | -3.0% | -0.5% | +1.5% | -5.4% | +4.4% | +4.6% | — |
| Nov 17, 2023 | BMO | -0.94 | -0.81 | +13.8% | 24.01 | +3.6% | +3.0% | -4.2% | +0.4% | +2.8% | -1.7% | — |
| Aug 4, 2023 | AMC | -1.14 | -1.01 | +11.4% | 22.98 | -0.4% | +3.4% | -1.8% | -3.1% | +0.8% | -2.1% | — |
| May 5, 2023 | AMC | -1.09 | -1.06 | +2.8% | 12.89 | +0.2% | +4.0% | +0.9% | -2.3% | -3.9% | -5.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 9 | UBS | Initiates | Neutral | $144 | $128.06 | $126.51 | -1.2% | -2.0% | +1.1% | +0.3% | +5.9% | +2.5% |
| Sep 9 | BWS Financial | Initiates | Sell | $45 | $128.06 | $126.51 | -1.2% | -2.0% | +1.1% | +0.3% | +5.9% | +2.5% |
| Jul 6 | Evercore ISI | Downgrade | Outperform → In-line | $102 | $99.24 | $96.80 | -2.5% | +0.7% | -8.9% | -1.8% | +4.8% | -3.2% |
| Jun 15 | Canaccord Genuity | Initiates | Buy | $90 | $76.17 | $79.35 | +4.2% | +6.1% | +5.1% | -2.4% | +5.7% | -2.7% |
| May 5 | Leerink Partners | Upgrade | Market Perform → Outperform | $70 | $56.19 | $58.32 | +3.8% | +0.9% | +5.0% | -1.7% | -2.9% | -1.1% |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $50.38 | $51.00 | +1.2% | +14.0% | +0.4% | -2.4% | +6.4% | +3.5% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $50.21 | $50.21 | +0.0% | +1.9% | -2.1% | +2.1% | -4.6% | -1.9% |
| Mar 30 | Guggenheim | Maintains | Buy → Buy | — | $44.53 | $45.33 | +1.8% | -2.9% | +9.8% | +4.3% | +1.4% | +1.9% |
| Feb 3 | Barclays | Maintains | Overweight → Overweight | — | $46.81 | $46.62 | -0.4% | -1.0% | +3.9% | -2.1% | +4.5% | -3.6% |
| Feb 3 | Evercore ISI | Maintains | Outperform → Outperform | — | $46.81 | $46.62 | -0.4% | -1.0% | +3.9% | -2.1% | +4.5% | -3.6% |
| Jan 26 | Guggenheim | Maintains | Buy → Buy | — | $42.94 | $42.68 | -0.6% | -1.1% | +0.3% | -1.4% | -1.0% | -1.2% |
| Jan 8 | TD Cowen | Maintains | Buy → Buy | — | $36.55 | $36.19 | -1.0% | -5.0% | +1.7% | +7.7% | +5.7% | -0.5% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $30.93 | $31.78 | +2.7% | +0.5% | +0.2% | +3.2% | -0.7% | +1.8% |
| Nov 17 | Barclays | Maintains | Overweight → Overweight | — | $26.87 | $26.74 | -0.5% | -1.5% | -1.7% | -2.1% | +2.4% | +9.6% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $31.85 | $32.14 | +0.9% | -2.3% | +5.4% | -2.7% | -2.2% | -3.4% |
| Oct 2 | Barclays | Maintains | Overweight → Overweight | — | $29.26 | $29.44 | +0.6% | +4.9% | +1.3% | +2.5% | -2.3% | +5.4% |
| May 6 | JP Morgan | Maintains | Underweight → Underweight | — | $35.93 | $35.31 | -1.7% | -8.9% | +0.1% | -0.5% | -5.5% | +6.9% |
| May 6 | Goldman Sachs | Maintains | Buy → Buy | — | $35.93 | $35.31 | -1.7% | -8.9% | +0.1% | -0.5% | -5.5% | +6.9% |
| May 6 | Guggenheim | Maintains | Buy → Buy | — | $35.93 | $35.31 | -1.7% | -8.9% | +0.1% | -0.5% | -5.5% | +6.9% |
| May 6 | Baird | Maintains | Outperform → Outperform | — | $35.93 | $35.31 | -1.7% | -8.9% | +0.1% | -0.5% | -5.5% | +6.9% |
| Apr 10 | Barclays | Maintains | Overweight → Overweight | — | $40.27 | $37.84 | -6.0% | -9.0% | +6.1% | +2.5% | -0.8% | -2.7% |
| Feb 4 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $52.75 | $53.39 | +1.2% | -1.4% | +3.2% | +0.1% | -2.6% | -7.0% |
| Feb 4 | Baird | Maintains | Outperform → Outperform | — | $52.75 | $53.39 | +1.2% | -1.4% | +3.2% | +0.1% | -2.6% | -7.0% |
| Feb 4 | JP Morgan | Maintains | Underweight → Underweight | — | $52.75 | $53.39 | +1.2% | -1.4% | +3.2% | +0.1% | -2.6% | -7.0% |
| Nov 26 | TD Cowen | Maintains | Buy → Buy | — | $46.40 | $46.58 | +0.4% | -0.1% | +4.3% | +1.8% | +2.3% | +0.6% |
| Nov 19 | Barclays | Maintains | Overweight → Overweight | — | $41.43 | $41.72 | +0.7% | -0.3% | -0.5% | +1.3% | +1.4% | +9.9% |
| Nov 19 | Baird | Maintains | Outperform → Outperform | — | $41.43 | $41.72 | +0.7% | -0.3% | -0.5% | +1.3% | +1.4% | +9.9% |
| Nov 19 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $41.43 | $41.72 | +0.7% | -0.3% | -0.5% | +1.3% | +1.4% | +9.9% |
| Oct 17 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $45.07 | $45.24 | +0.4% | +1.0% | +3.1% | -3.4% | -3.4% | -6.2% |
| Oct 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $45.18 | $44.63 | -1.2% | -3.9% | -0.3% | -1.1% | +1.3% | -2.7% |
| Aug 5 | Barclays | Maintains | Overweight → Overweight | — | $42.97 | $38.99 | -9.3% | +5.5% | +2.0% | -3.7% | +2.0% | -3.2% |
| Aug 5 | Baird | Maintains | Outperform → Outperform | — | $42.97 | $38.99 | -9.3% | +5.5% | +2.0% | -3.7% | +2.0% | -3.2% |
| Aug 5 | JP Morgan | Maintains | Underweight → Underweight | — | $42.97 | $38.99 | -9.3% | +5.5% | +2.0% | -3.7% | +2.0% | -3.2% |
| Jul 9 | Goldman Sachs | Maintains | Buy → Buy | — | $48.95 | $49.13 | +0.4% | +3.2% | +1.0% | +2.9% | +1.8% | +5.1% |
| Jun 28 | Barclays | Maintains | Overweight → Overweight | — | $47.48 | $48.29 | +1.7% | +3.8% | -0.7% | -3.3% | +1.4% | +1.0% |
| Jun 13 | TD Cowen | Maintains | Buy → Buy | — | $52.44 | $52.98 | +1.0% | -0.8% | -4.2% | -1.7% | +3.2% | -3.6% |
| May 6 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $41.21 | $41.48 | +0.7% | +8.4% | -3.4% | -4.0% | +4.3% | -1.9% |
| May 3 | Evercore ISI | Maintains | Outperform → Outperform | — | $32.01 | $38.28 | +19.6% | +28.7% | +8.4% | -3.4% | -4.0% | +4.3% |
| May 3 | Baird | Maintains | Outperform → Outperform | — | $32.01 | $38.28 | +19.6% | +28.7% | +8.4% | -3.4% | -4.0% | +4.3% |
| May 3 | Barclays | Maintains | Overweight → Overweight | — | $32.01 | $38.28 | +19.6% | +28.7% | +8.4% | -3.4% | -4.0% | +4.3% |
| Apr 10 | Barclays | Maintains | Overweight → Overweight | — | $33.73 | $31.32 | -7.1% | -5.5% | +2.6% | -6.1% | -4.7% | -2.2% |
| Feb 5 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $36.59 | $35.50 | -3.0% | -0.5% | +1.5% | -5.4% | +4.4% | +4.6% |
| Jan 25 | Barclays | Maintains | Overweight → Overweight | — | $32.67 | $33.57 | +2.8% | -0.8% | -0.4% | +7.7% | -4.5% | -2.4% |
| Jan 18 | Goldman Sachs | Maintains | Buy → Buy | — | $34.84 | $35.35 | +1.5% | -2.8% | -0.7% | +3.5% | -1.0% | -5.0% |
| Jan 17 | Goldman Sachs | Upgrade | Neutral → Buy | — | $35.27 | $37.68 | +6.8% | -1.2% | -2.8% | -0.7% | +3.5% | -1.0% |
| Aug 7 | Barclays | Maintains | Overweight → Overweight | — | $22.98 | $22.89 | -0.4% | +3.4% | -1.8% | -3.1% | +0.8% | -2.1% |
| Jul 13 | Goldman Sachs | Maintains | Neutral → Neutral | — | $23.21 | $23.60 | +1.7% | +0.7% | -0.3% | +3.7% | +3.8% | +3.7% |
| May 8 | Baird | Maintains | Outperform → Outperform | — | $12.89 | $12.91 | +0.2% | +4.0% | +0.9% | -2.3% | -3.9% | -5.9% |
| May 8 | Barclays | Maintains | Overweight → Overweight | — | $12.89 | $12.91 | +0.2% | +4.0% | +0.9% | -2.3% | -3.9% | -5.9% |
| Apr 19 | Goldman Sachs | Maintains | Neutral → Neutral | — | $14.37 | $13.95 | -2.9% | +0.2% | -6.1% | +1.7% | -0.9% | -6.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | WERNER ROBERT F. | Chief Accounting Officer | Sell | 238 | $122.62 | $29K | 44,399 | +0.29% | +8.73% |
| Sep 8, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 2,302 | $122.62 | $282K | 768,427 | +0.29% | +8.73% |
| Sep 8, 2026 | Green Paula | SVP of Human Resources | Sell | 907 | $122.62 | $111K | 117,014 | +0.29% | +8.73% |
| Sep 8, 2026 | Cho Dennis | See Remarks | Sell | 412 | $122.62 | $51K | 73,651 | +0.29% | +8.73% |
| Aug 25, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 1,093 | $154.45 | $169K | 770,729 | -7.66% | -1.75% |
| Aug 25, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 9,181 | $153.93 | $1.4M | 771,822 | -7.66% | -1.75% |
| Aug 25, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 6,412 | $152.75 | $979K | 781,003 | -7.66% | -1.75% |
| Aug 25, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 12,236 | $151.35 | $1.9M | 787,415 | -7.66% | -1.75% |
| Aug 25, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 12,648 | $150.56 | $1.9M | 799,651 | -7.66% | -1.75% |
| Aug 24, 2026 | WERNER ROBERT F. | Chief Accounting Officer | Sell | 854 | $140.77 | $120K | 44,637 | -0.90% | -4.99% |
| Aug 21, 2026 | WERNER ROBERT F. | Chief Accounting Officer | Sell | 669 | $139.07 | $93K | 45,491 | -0.90% | -4.99% |
| Aug 21, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 6,639 | $139.07 | $923K | 812,299 | -0.90% | -4.99% |
| Aug 21, 2026 | Laponis Adam | Chief Financial Officer | Sell | 1,965 | $139.07 | $273K | 108,633 | -0.90% | -4.99% |
| Aug 21, 2026 | Green Paula | SVP of Human Resources | Sell | 1,360 | $139.07 | $189K | 117,921 | -0.90% | -4.99% |
| Aug 21, 2026 | Finn Patrick John | President and COO | Sell | 4,046 | $139.07 | $563K | 210,802 | -0.90% | -4.99% |
| Aug 21, 2026 | Cho Dennis | See Remarks | Sell | 1,598 | $139.07 | $222K | 74,063 | -0.90% | -4.99% |
| Aug 19, 2026 | Cho Dennis | See Remarks | Sell | 14,205 | $129.75 | $1.8M | 75,661 | -3.29% | -7.66% |
| Aug 18, 2026 | Finn Patrick John | President and COO | Sell | 2,000 | $122.58 | $245K | 214,678 | +6.79% | +2.03% |
| Aug 18, 2026 | Finn Patrick John | President and COO | Sell | 6,296 | $121.01 | $762K | 216,678 | +6.79% | +2.03% |
| Aug 18, 2026 | Finn Patrick John | President and COO | Sell | 12,917 | $119.86 | $1.5M | 222,974 | +6.79% | +2.03% |
| Aug 18, 2026 | Finn Patrick John | President and COO | Sell | 4,500 | $119.04 | $536K | 235,891 | +6.79% | +2.03% |
| Aug 18, 2026 | Finn Patrick John | President and COO | Sell | 8,868 | $117.70 | $1.0M | 240,391 | +6.79% | +2.03% |
| Aug 18, 2026 | Finn Patrick John | President and COO | Sell | 10,420 | $116.82 | $1.2M | 249,259 | +6.79% | +2.03% |
| Aug 18, 2026 | Finn Patrick John | President and COO | Sell | 33,354 | $115.90 | $3.9M | 259,679 | +6.79% | +2.03% |
| Aug 12, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 19,952 | $125.08 | $2.5M | 818,938 | +4.93% | +6.79% |
| Aug 12, 2026 | BLAKE KATRYN | — | Sell | 2,240 | $122.88 | $275K | 17,208 | +4.93% | +6.79% |
| Aug 10, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 113,318 | $125.16 | $14.2M | 818,938 | +0.06% | +22.64% |
| Aug 7, 2026 | CHESS ROBERT | — | Sell | 18,417 | $110.89 | $2.0M | 21,084 | +1.70% | -6.68% |
| Aug 5, 2026 | Cho Dennis | See Remarks | Sell | 14,205 | $109.75 | $1.6M | 89,866 | +7.96% | -5.36% |
| Aug 3, 2026 | Cho Dennis | See Remarks | Sell | 1,070 | $85.32 | $91K | 104,071 | -5.16% | +1.70% |
8-K · 7.01
! Medium
Twist Bioscience Corporation -- 8-K 7.01: Regulation FD Disclosure
Aug 19
8-K · 2.02
!! High
Twist Bioscience Corporation -- 8-K 2.02: Earnings Results
Twist Bioscience announced Q2 2026 earnings results, with detailed financial performance metrics now publicly available for investor evaluation and analysis.
Aug 3
8-K · 2.02
!! High
Twist Bioscience Corporation -- 8-K 2.02: Earnings Results
Twist Bioscience released Q1 2026 earnings results, providing investors with updated financial performance and operational metrics for the quarter ended March 31, 2026.
May 4
8-K · 8.01
!! High
Twist Bioscience Corporation -- 8-K 8.01: Material Event / Announcement
Twist Bioscience secured investor commitments with registration rights agreements, enabling shareholders to liquidate holdings through registered public offerings, reducing lock-up restrictions.
Feb 17
8-K
Twist Bioscience Corporation -- 8-K Filing
I cannot provide a meaningful analysis from this filing summary, as it contains only technical metadata and schema references without substantive business information.
Feb 6
8-K
Twist Bioscience Corporation -- 8-K Filing
Twist Bioscience exceeded expectations with record $103.7M quarterly revenue, 17% year-over-year growth, and raised full-year guidance to $435-440M, signaling strong momentum in synthetic biology markets.
Feb 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 5,833,891 | $600M | New | Jun 2026 |
| 2 | Ark Investment Management Llc | 4,549,803 | $468M | Reduced | Jun 2026 |
| 3 | Artisan Partners Limited Partnership | 6,367,777 | $303M | Added | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 2,824,989 | $291M | Added | Jun 2026 |
| 5 | Vanguard Capital Management Llc | 2,699,280 | $278M | Added | Jun 2026 |
| 6 | William Blair Investment Management, Llc | 2,174,594 | $224M | Reduced | Jun 2026 |
| 7 | Farallon Capital Management, L.l.c. | 2,136,400 | $220M | Added | Jun 2026 |
| 8 | Citadel Advisors Llc | 1,724,084 | $177M | Reduced | Jun 2026 |
| 9 | Edgepoint Investment Group Inc. | 5,377,991 | $171M | Added | Dec 2025 |
| 10 | D. E. Shaw & Co., Inc. | 1,185,605 | $122M | Added | Jun 2026 |
| 11 | Invesco Ltd. | 2,171,898 | $103M | Added | Mar 2026 |
| 12 | Sumitomo Mitsui Trust Group, Inc. | 1,000,344 | $103M | New | Jun 2026 |
| 13 | Fmr Llc | 1,889,945 | $90M | Added | Mar 2026 |
| 14 | Morgan Stanley | 1,732,712 | $55M | Reduced | Dec 2025 |
| 15 | Nuveen, Llc | 522,043 | $54M | Added | Jun 2026 |
| 16 | Jennison Associates Llc | 453,216 | $47M | Reduced | Jun 2026 |
| 17 | Allspring Global Investments Holdings, Llc | 418,129 | $43M | Reduced | Jun 2026 |
| 18 | Tao Capital Management Lp | 828,815 | $39M | — | Mar 2026 |
| 19 | Millennium Management Llc | 347,148 | $36M | Reduced | Jun 2026 |
| 20 | Sei Investments Co | 294,931 | $30M | Reduced | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$9.99B
Enterprise Value
$9.82B
P/E (TTM)
-75.22x
Forward P/E
—
PEG Ratio
0.34x
P/B
21.12x
P/S
23.13x
P/FCF
-132.05x
EV/EBITDA
—
Shares Out
59.8M
Financials (TTM)
Revenue
$431.8M
Net Income
-$136.7M
EBITDA
-$107.8M
Free Cash Flow
-$75.6M
Op Cash Flow
-$47.6M
EPS Basic
$-1.30
EPS Diluted
$-2.22
EPS Forward
$-1.67
Gross Margin
52.0%
Op Margin
-31.9%
Net Margin
-31.7%
Balance Sheet
Total Assets
$641.9M
Total Liab.
$168.9M
Total Equity
$473.0M
Cash
$232.4M
LT Debt
$61.8M
Book Value/Sh
$7.91
Debt/Equity
0.29x
Current Ratio
3.64
Quick Ratio
3.33
Returns & Growth
ROE
-16.8%
ROA
-12.0%
ROIC
-24.1%
Rev Growth YoY
+20.3%
EPS Growth YoY
+63.9%
Price Returns
2W
+18.7%
1M
+34.0%
3M
+77.7%
6M
+249.9%
12M
+456.6%
Technicals
52W High
$166.99
52W Low
$25.45
50d MA
$118.31
200d MA
$69.68
RSI (14)
70.00
ATR (14)
$9.21
Beta
2.21
Avg Volume
1.7M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$49.50
High
$55.00
Low
$41.00
Median
$51.00
Data updated apr 27, 2026 6:13am
· Source: financialmodelingprep.com